Dept of Cardiology, Isfahan University of Medical Sciences, Isfahan, Iran.
Int J Cardiol. 2013 Aug 20;167(4):1560-9. doi: 10.1016/j.ijcard.2012.04.094. Epub 2012 Jun 7.
Enhanced attraction of selective vascular reparative cells is of great importance in order to increase vascular patency after endovascular treatments. We aimed to evaluate efficient attachment of endothelial cells and their progenitors on surfaces coated with mixture of specific antibodies, L-selectin and VE-cadherin, with prohibited platelet attachment.
The most efficient conditions for coating of L-selectin-Fc chimera and VE-cadherin-Fc chimera proteins were first determined by protein coating on ELISA plates. The whole processes were repeated on titanium substrates, which are commonly used to coat stents. Endothelial progenitor cells (EPCs) and human umbilical vein endothelial cells (HUVECs) were isolated and characterized by flow cytometry. Cell attachment, growth, proliferation, viability and surface cytotoxicity were evaluated using nuclear staining and MTT assay. Platelet and cell attachment were evaluated using scanning electron microscopy.
Optimal concentration of each protein for surface coating was 50 ng/ml. The efficacy of protein coating was both heat and pH independent. Calcium ions had significant impact on simultaneous dual-protein coating (P<0.05). Coating stability data revealed more than one year stability for these coated proteins at 4°C. L-selectin and VE-cadherin (ratio of 50:50) coated surface showed highest EPC and HUVEC attachment, viability and proliferation compared to single protein coated and non-coated titanium surfaces (P<0.05). This double coated surface did not show any cytotoxic effect.
Surfaces coated with L-selectin and VE-cadherin are friendly surface for EPC and endothelial cell attachment with less platelet attachment. These desirable factors make the L-selectin and VE-cadherin coated surfaces perfect candidate endovascular device.
为了提高血管内治疗后的血管通畅率,增强选择性血管修复细胞的吸引力非常重要。我们旨在评估内皮细胞及其前体细胞在涂有混合特定抗体、L-选择素和 VE-钙粘蛋白的表面上的有效附着,同时阻止血小板附着。
首先通过 ELISA 板上的蛋白质涂层确定 L-选择素-Fc 嵌合体和 VE-钙粘蛋白-Fc 嵌合体蛋白的最有效涂层条件。整个过程在钛基底上重复进行,钛基底通常用于涂覆支架。通过流式细胞术分离和表征内皮祖细胞(EPCs)和人脐静脉内皮细胞(HUVECs)。使用核染色和 MTT 测定评估细胞附着、生长、增殖、活力和表面细胞毒性。使用扫描电子显微镜评估血小板和细胞附着。
表面涂层的每种蛋白质的最佳浓度为 50ng/ml。蛋白质涂层的效果不受热和 pH 值的影响。钙离子对双蛋白同时涂层有显著影响(P<0.05)。涂层稳定性数据表明,这些涂层蛋白在 4°C 下可稳定保存一年以上。与单独的蛋白质涂层和非涂层钛表面相比,L-选择素和 VE-钙粘蛋白(比例为 50:50)涂层表面显示出更高的 EPC 和 HUVEC 附着、活力和增殖(P<0.05)。这种双涂层表面没有显示出任何细胞毒性作用。
涂有 L-选择素和 VE-钙粘蛋白的表面对 EPC 和内皮细胞附着友好,血小板附着较少。这些理想的因素使 L-选择素和 VE-钙粘蛋白涂层表面成为理想的血管内装置候选物。